{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:04:23Z","timestamp":1793729063926,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1053206"],"award-info":[{"award-number":["APP1053206"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1108422"],"award-info":[{"award-number":["APP1108422"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2001692"],"award-info":[{"award-number":["APP2001692"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1107178"],"award-info":[{"award-number":["APP1107178"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.aohep.2024.101512","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T05:16:38Z","timestamp":1714972598000},"page":"101512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Ziyan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moutaz","family":"Derbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AlNaamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Ghazinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.aohep.2024.101512_bib0001","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"10.1016\/j.aohep.2024.101512_bib0002","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight","volume":"19","author":"Eslam","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2024.101512_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","author":"Miao","year":"2024","journal-title":"Trends in Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.aohep.2024.101512_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.aohep.2024.101512_bib0005","first-page":"1","article-title":"MAFLD and chronic kidney disease: two sides of the same coin?","author":"Pan","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2024.101512_bib0006","first-page":"1","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","author":"Feng","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2024.101512_bib0007","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S2468-1253(20)30090-X","article-title":"Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health","volume":"5","author":"Eslam","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101512_bib0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2024.101512_bib0009","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.aohep.2024.101512_bib0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101512_bib0011","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3350\/cmh.2021.0310","article-title":"MAFLD enhances clinical practice for liver disease in the Asia-Pacific region","volume":"28","author":"Kawaguchi","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101512_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic dysfunction-associated fatty liver disease: a year in review","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.aohep.2024.101512_bib0013","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2024.101512_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.aohep.2024.101512_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/gastro\/got007","article-title":"Update of liver fibrosis and steatosis with transient elastography (Fibroscan)","volume":"1","author":"Wong","year":"2013","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"6","key":"10.1016\/j.aohep.2024.101512_bib0016","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"9","key":"10.1016\/j.aohep.2024.101512_bib0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.aohep.2024.101512_bib0018","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatology Research"},{"issue":"12","key":"10.1016\/j.aohep.2024.101512_bib0019","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2024.101512_bib0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ndt\/gfac188","article-title":"Metabolic dysfunction\u2013associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease","volume":"38","author":"Tanaka","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.aohep.2024.101512_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.03.042","article-title":"The MASLD criteria overlook a number of adolescent patients with severe steatosis","author":"Pan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2024.101512_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15931","article-title":"MAFLD predicts cardiovascular disease risk better than MASLD","author":"Pan","year":"2024","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.aohep.2024.101512_bib0023","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/liv.15878","article-title":"Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort","volume":"44","author":"Tang","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2024.101512_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","author":"Semmler","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.aohep.2024.101512_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.11.001","article-title":"Definition of Metabolic Dysfunction: shifting Goalposts","volume":"14","author":"Anirvan","year":"2023","journal-title":"J Clin Exp Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124003065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124003065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:39:53Z","timestamp":1778621993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268124003065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1665268124003065"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101512","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101512"}}